Abbott Introduces New ALK Genetic Test for Specific Form of Lung Cancer

Abbott ABT today announced the availability of a new molecular test in the European Union and New Zealand designed to identify the presence of gene rearrangements associated with a specific form of non-small-cell lung cancer.  These rearrangements in a gene known as ALK have been implicated in the formation of cancerous tumors in patients with NSCLC.